^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    Chr t(11;14)

    Apply
    Acalabrutinib with or Without Obinutuzumab in Treating Patients with Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT03516617)
    Phase 2
    Mayo Clinic
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    09/10/2018
    Primary completion :
    03/15/2030
    Completion :
    03/15/2031
    CD20 • CCND1 • CD5 • FCER2
    |
    Chr t(11;14)
    |
    Gazyva (obinutuzumab) • Calquence (acalabrutinib)
    Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis (NCT04847453)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    08/03/2022
    Primary completion :
    06/30/2026
    Completion :
    06/30/2026
    BCL2 • MCL1 • BCL2L1 • SDC1 • BAX
    |
    Chr t(11;14)
    |
    Venclexta (venetoclax) • Ninlaro (ixazomib) • dexamethasone • Hemady (dexamethasone tablets)
    Allogenic CD19-targeting CAR-γδT Cell Therapy in r/r NHL (NCT05554939)
    Phase 1/2
    Chinese PLA General Hospital
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    12/11/2022
    Primary completion :
    12/31/2026
    Completion :
    12/31/2027
    BCL2 • CCND1 • BCL6
    |
    CD19 positive • Chr t(11;14)
    |
    cyclophosphamide • fludarabine IV • Mustargen (mechlorethamine)
    A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients with Previously Untreated High-risk Mantle Cell Lymphoma (NCT05495464)
    Phase 1
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    02/12/2025
    Initiation :
    11/18/2022
    Primary completion :
    03/31/2027
    Completion :
    03/31/2027
    TP53 • CD20 • CCND1 • KMT2D • NOTCH2 • BIRC3 • FAT1 • POT1 • NSD2 • UBR5
    |
    CD20 positive • Chr t(11;14)
    |
    Rituxan (rituximab) • cyclophosphamide • Calquence (acalabrutinib) • fludarabine IV • Tecartus (brexucabtagene autoleucel)
    Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia (NCT03701282)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/10/2025
    Initiation :
    02/12/2019
    Primary completion :
    05/07/2028
    Completion :
    05/07/2028
    CD20 • CCND1 • CD5 • FCER2
    |
    Chr t(11;14)
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • Gazyva (obinutuzumab)
    Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia (A041702) (NCT03737981)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/10/2025
    Initiation :
    01/31/2019
    Primary completion :
    06/01/2027
    Completion :
    06/01/2027
    CD20 • CD5 • FCER2
    |
    Chr t(11;14)
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • Gazyva (obinutuzumab)
    A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma (GLOBRYTE) (NCT06084936)
    Phase 3
    Hoffmann-La Roche
    Recruiting
    Last update posted :
    02/07/2025
    Initiation :
    10/22/2023
    Primary completion :
    03/31/2026
    Completion :
    06/30/2027
    CCND1
    |
    Chr t(11;14)
    |
    Rituxan (rituximab) • lenalidomide • Gazyva (obinutuzumab) • bendamustine • Actemra IV (tocilizumab) • Columvi (glofitamab-gxbm)
    Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma (NCT02159755)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/04/2025
    Initiation :
    05/20/2014
    Primary completion :
    06/25/2018
    Completion :
    01/20/2026
    CCND1 • CD5
    |
    Chr t(11;14)
    |
    Ibrance (palbociclib) • Imbruvica (ibrutinib)
    A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma (EPCORE NHL-5) (NCT05283720)
    Phase 2
    Genmab
    Recruiting
    Last update posted :
    02/04/2025
    Initiation :
    06/14/2022
    Primary completion :
    11/01/2032
    Completion :
    11/01/2032
    BCL2 • CD20 • CCND1 • BCL6
    |
    Chr t(11;14)
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • prednisone • Jaypirca (pirtobrutinib) • Epkinly (epcoritamab-bysp) • Polivy (polatuzumab vedotin-piiq) • golcadomide (CC-99282)
    Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma (NCI-2018-00315) (NCT03479268)
    Phase 1
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    01/29/2025
    Initiation :
    03/22/2018
    Primary completion :
    06/22/2025
    Completion :
    06/22/2025
    CCND1 • FCER2
    |
    Chr t(11;14)
    |
    Imbruvica (ibrutinib) • pevonedistat (MLN4924)
    A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL (NCT02135133)
    Phase 2
    Dana-Farber Cancer Institute
    Completed
    Last update posted :
    10/16/2024
    Initiation :
    06/01/2014
    Primary completion :
    10/06/2020
    Completion :
    10/06/2020
    CD19 • CCND1 • CD5 • FCER2
    |
    Chr t(11;14)
    |
    Zydelig (idelalisib) • Arzerra (ofatumumab)
    Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma (ZEBRA) (NCT05635162)
    Phase 2
    University College, London
    Recruiting
    Last update posted :
    06/12/2024
    Initiation :
    05/17/2024
    Primary completion :
    10/01/2028
    Completion :
    10/01/2028
    CCND1
    |
    Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
    |
    Rituxan (rituximab) • Brukinsa (zanubrutinib)
    Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis (NCT06022939)
    Phase 3
    SWOG Cancer Research Network
    Not yet recruiting
    Last update posted :
    06/11/2024
    Initiation :
    07/01/2024
    Primary completion :
    07/29/2030
    Completion :
    10/29/2030
    CD34
    |
    Chr t(11;14)
    |
    bortezomib • cyclophosphamide • melphalan • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Hemady (dexamethasone tablets) • dexamethasone injection
    Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) (BELLWAVE-003) (NCT04728893)
    Phase 2
    Merck Sharp & Dohme LLC
    Recruiting
    Last update posted :
    06/07/2024
    Initiation :
    04/05/2021
    Primary completion :
    03/19/2027
    Completion :
    03/19/2027
    TP53 • CCND1 • CD4
    |
    TP53 mutation • Chr t(11;14) • CCND1 overexpression
    |
    nemtabrutinib (MK-1026)
    Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (ECOG-ACRIN E1912) (NCT02048813)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    06/07/2024
    Initiation :
    02/20/2014
    Primary completion :
    10/24/2018
    Completion :
    12/31/2024
    CD20 • CCND1 • IGH • CD4 • CD5 • FCER2
    |
    Chr t(11;14) • CD4 positive
    |
    Imbruvica (ibrutinib) • Rituxan (rituximab) • cyclophosphamide • Truxima (rituximab-abbs) • fludarabine IV • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • cyclophosphamide intravenous
    A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma (SHINE ) (NCT01776840)
    Phase 3
    Janssen Research & Development, LLC
    Active, not recruiting
    Last update posted :
    06/07/2024
    Initiation :
    05/01/2013
    Primary completion :
    06/01/2021
    Completion :
    06/01/2024
    CD20 • CCND1 • PAX5 • CD5
    |
    Chr t(11;14) • CCND1 expression
    |
    Imbruvica (ibrutinib) • Rituxan (rituximab) • bendamustine
    Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (ALLIANCE A041202) (NCT01886872)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    06/07/2024
    Initiation :
    12/09/2013
    Primary completion :
    08/07/2018
    Completion :
    01/30/2025
    CD20 • CD4 • CD5 • FCER2
    |
    Chr t(11;14)
    |
    Imbruvica (ibrutinib) • Rituxan (rituximab) • bendamustine • Truxima (rituximab-abbs) • Belrapzo (bendamustine RTD) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar)
    A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) (topMIND) (NCT04809467)
    Phase 1/2
    Incyte Corporation
    Active, not recruiting
    Last update posted :
    06/06/2024
    Initiation :
    09/16/2021
    Primary completion :
    12/15/2024
    Completion :
    12/15/2024
    BCL2 • CCND1 • BCL6
    |
    Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • BCL2 rearrangement
    |
    parsaclisib (INCB50465) • Monjuvi (tafasitamab-cxix)
    Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (NCT04939272)
    Phase 1/2
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    06/04/2024
    Initiation :
    06/29/2022
    Primary completion :
    11/23/2024
    Completion :
    11/23/2024
    BCL2 • CD20 • CCND1 • PAX5 • CD5
    |
    Chr t(11;14) • CCND1 overexpression • PAX5 overexpression
    |
    Venclexta (venetoclax) • Aliqopa (copanlisib)
    Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma (NCT05976763)
    Phase 3
    Alliance for Clinical Trials in Oncology
    Recruiting
    Last update posted :
    05/23/2024
    Initiation :
    09/08/2023
    Primary completion :
    08/31/2038
    Completion :
    08/31/2038
    CCND1
    |
    Chr t(11;14) • CCND1 expression
    |
    Rituxan (rituximab) • Brukinsa (zanubrutinib)
    Study of Tazemetostat in Lymphoid Malignancies (NCT05983965)
    Phase 1
    University of Alabama at Birmingham
    Not yet recruiting
    Last update posted :
    05/08/2024
    Initiation :
    08/01/2024
    Primary completion :
    06/01/2028
    Completion :
    12/01/2029
    CD4
    |
    Chr t(11;14) • CCND1 expression
    |
    Calquence (acalabrutinib) • Tazverik (tazemetostat)
    Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma (NCT04189757)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    05/08/2024
    Initiation :
    08/07/2020
    Primary completion :
    06/30/2025
    Completion :
    06/30/2025
    CD20 • CCND1
    |
    CD20 positive • Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
    |
    Imbruvica (ibrutinib) • Calquence (acalabrutinib)
    Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency (NCT01787409)
    Phase N/A
    Mayo Clinic
    Recruiting
    Last update posted :
    05/07/2024
    Initiation :
    03/06/2013
    Primary completion :
    03/28/2025
    Completion :
    03/28/2025
    CD20 • CCND1 • CD5 • FCER2 • VDR
    |
    Chr t(11;14)
    Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma (NCT03478514)
    Phase 2
    Alliance Foundation Trials, LLC.
    Active, not recruiting
    Last update posted :
    05/06/2024
    Initiation :
    09/11/2018
    Primary completion :
    06/30/2025
    Completion :
    12/01/2025
    CCND1 • CD4 • CD5
    |
    Chr t(11;14)
    |
    Ibrance (palbociclib) • Imbruvica (ibrutinib)
    Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients (NCT05529069)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    04/24/2024
    Initiation :
    01/25/2023
    Primary completion :
    04/28/2027
    Completion :
    04/28/2027
    TP53 • MYC • BCL2 • CDKN2A • CCND1 • NOTCH2 • NSD2
    |
    TP53 mutation • Chr del(17p) • Chr t(11;14) • CDKN2A mutation • CCND1 overexpression • Chr t(11;14)(q13;q32) • MYC positive • BCL2 amplification
    |
    Venclexta (venetoclax) • Jaypirca (pirtobrutinib)
    Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma (NCT03946878)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    04/18/2024
    Initiation :
    08/13/2019
    Primary completion :
    02/08/2026
    Completion :
    02/08/2026
    CCND1
    |
    Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
    |
    Venclexta (venetoclax) • Calquence (acalabrutinib)
    Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma (NCT04402138)
    Phase 2
    SCRI Development Innovations, LLC
    Completed
    Last update posted :
    04/15/2024
    Initiation :
    08/07/2020
    Primary completion :
    04/05/2024
    Completion :
    04/05/2024
    CCND1
    |
    Chr t(11;14)
    |
    Calquence (acalabrutinib)
    Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) (NCT02631044)
    Phase 1
    Juno Therapeutics, a Subsidiary of Celgene
    Active, not recruiting
    Last update posted :
    03/27/2024
    Initiation :
    01/06/2016
    Primary completion :
    05/10/2024
    Completion :
    05/10/2024
    BCL2 • CCND1 • BCL6
    |
    CD19 positive • Chr t(11;14) • BCL6 rearrangement • CCND1 expression • BCL2 rearrangement
    |
    Breyanzi (lisocabtagene maraleucel)
    Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma (NCT03872180)
    Phase 2
    Emory University
    Active, not recruiting
    Last update posted :
    03/21/2024
    Initiation :
    04/11/2019
    Primary completion :
    09/06/2024
    Completion :
    04/30/2026
    CCND1
    |
    Chr t(11;14)
    |
    Venclexta (venetoclax) • Gazyva (obinutuzumab) • bendamustine
    Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL) (NCT05008055)
    Phase 2
    AstraZeneca
    Active, not recruiting
    Last update posted :
    03/18/2024
    Initiation :
    11/03/2021
    Primary completion :
    08/22/2023
    Completion :
    06/28/2024
    CCND1
    |
    Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
    |
    Truqap (capivasertib)
    Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance (LYMA-101) (NCT02896582)
    Phase 2
    The Lymphoma Academic Research Organisation
    Active, not recruiting
    Last update posted :
    03/15/2024
    Initiation :
    10/01/2016
    Primary completion :
    03/01/2019
    Completion :
    03/01/2025
    CD20 • CCND1 • CD5
    |
    Chr t(11;14) • CD20 expression • CCND1 expression
    |
    cisplatin • cytarabine • Gazyva (obinutuzumab) • etoposide IV • dexamethasone • carmustine • melphalan
    A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL (ACE-LY-308) (NCT02972840)
    Phase 3
    Acerta Pharma BV
    Active, not recruiting
    Last update posted :
    03/08/2024
    Initiation :
    04/05/2017
    Primary completion :
    10/28/2025
    Completion :
    10/28/2025
    CD20 • CCND1 • PAX5 • CD5
    |
    Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
    |
    Rituxan (rituximab) • Calquence (acalabrutinib) • bendamustine • Rituxan Hycela (rituximab/hyaluronidase) • Belrapzo (bendamustine RTD)
    A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma (TrAVeRse) (NCT05951959)
    Phase 2
    AstraZeneca
    Recruiting
    Last update posted :
    03/06/2024
    Initiation :
    12/13/2023
    Primary completion :
    01/17/2029
    Completion :
    01/17/2029
    TP53 • BCL2 • CD20 • CCND1 • PAX5 • CD5
    |
    Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • Calquence (acalabrutinib)
    Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma (NCT03399539)
    Phase 1
    Mayo Clinic
    Completed
    Last update posted :
    03/04/2024
    Initiation :
    05/02/2018
    Primary completion :
    12/20/2021
    Completion :
    02/23/2024
    BCL2
    |
    Chr t(11;14)
    |
    Venclexta (venetoclax) • Ninlaro (ixazomib) • dexamethasone
    Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma (NCT05391750)
    Phase 1
    Emory University
    Recruiting
    Last update posted :
    02/28/2024
    Initiation :
    10/19/2022
    Primary completion :
    02/12/2026
    Completion :
    02/12/2027
    BCL2
    |
    Chr t(11;14)
    |
    Venclexta (venetoclax) • Actemra IV (tocilizumab)
    Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT03961672)
    Phase 2
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    02/15/2024
    Initiation :
    05/13/2020
    Primary completion :
    06/27/2024
    Completion :
    06/27/2024
    BCL2 • CCND1 • FCER2
    |
    Chr t(11;14) • CCND1 overexpression
    |
    Copiktra (duvelisib) • ETP-47187
    Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma (NCT03623373)
    Phase 2
    Washington University School of Medicine
    Active, not recruiting
    Last update posted :
    02/13/2024
    Initiation :
    11/29/2018
    Primary completion :
    02/09/2020
    Completion :
    02/05/2025
    CCND1 • CD34
    |
    Chr t(11;14)
    |
    Rituxan (rituximab) • cytarabine • Calquence (acalabrutinib) • bendamustine • Rituxan Hycela (rituximab/hyaluronidase) • Belrapzo (bendamustine RTD)
    RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia (CORONADO CLL) (NCT05405309)
    Phase 1/2
    University of Utah
    Recruiting
    Last update posted :
    02/13/2024
    Initiation :
    09/23/2022
    Primary completion :
    08/15/2025
    Completion :
    08/15/2027
    TP53 • BCL2 • CD20 • SF3B1 • CCND1 • CD5 • POT1 • FCER2
    |
    TP53 mutation • ATM mutation • Chr t(11;14) • SF3B1 mutation
    |
    Lynparza (olaparib) • camonsertib (RP-3500)
    Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma (ALTAMIRA) (NCT05214183)
    Phase 2
    Nordic Lymphoma Group
    Active, not recruiting
    Last update posted :
    02/12/2024
    Initiation :
    12/15/2021
    Primary completion :
    01/01/2027
    Completion :
    01/01/2027
    CCND1
    |
    Chr t(11;14)
    |
    Rituxan (rituximab) • Calquence (acalabrutinib)
    Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma (NCI-2011-03562) (NCT01527149)
    Phase 2
    Roswell Park Cancer Institute
    Completed
    Last update posted :
    02/07/2024
    Initiation :
    12/06/2011
    Primary completion :
    04/26/2018
    Completion :
    01/11/2024
    CD20 • CCND1 • IGH • CD5 • FCER2
    |
    Chr t(11;14) • CD20 expression
    |
    cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • dexamethasone • Arzerra (ofatumumab) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection • methotrexate IV
    Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL (NCT04697940)
    Phase 1/2
    Han weidong
    Recruiting
    Last update posted :
    02/07/2024
    Initiation :
    12/15/2020
    Primary completion :
    12/30/2024
    Completion :
    12/30/2025
    BCL2 • CCND1 • BCL6
    |
    Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • Chr t(11;14)(q13;q32) • BCL2 rearrangement • CD20 negative
    |
    cyclophosphamide • decitabine • fludarabine IV
    A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets (NCT05308654)
    Phase 1
    AbbVie
    Recruiting
    Last update posted :
    01/25/2024
    Initiation :
    05/17/2022
    Primary completion :
    08/28/2026
    Completion :
    08/28/2026
    BCL2
    |
    Chr t(11;14)
    |
    lenalidomide • Darzalex (daratumumab) • dexamethasone • ABBV-453